Table 1.
Changes of TSBAb (TSH-stimulation blocking antibody) and TSAb (thyroid stimulating antibody) over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive Graves' patients with hyperthyroidism.
| (I) 34 TSBAb-positive patients with hypothyroidism | 34 | ||
|---|---|---|---|
| Ia: Positive TSBAb persisted | Continued to have hypothyroidism | 17 | 17 |
| Ib: TSBAb disappeared | Ib1: Recovered from hypothyroidism | 13 | 15 |
| Ib2: Continued to have hypothyroidism | 2 | ||
| Ic: TSBAb → TSAb | TSBAb-positive hypo → Graves' hyper | 2 | 2 |
|
| |||
| (II) 98 TSAb-positive Graves' patients with hyperthyroidism | 98 | ||
|
| |||
| IIa: Positive TSAb persisted | Continued to have Graves' hyperthyroidism | 10 | 10 |
| IIb: Complex changes of TSAb | IIb1: Remission | 1 | 13 |
| IIb2: Recurrence | 12 | ||
| IIc: TSAb disappeared | IIc1: Remission | 60 | 73 |
| IIc2: Recurrence | 13 | ||
| IId: TSAb → TSBAb | Graves' hyper → TSBAb-positive hypo | 2 | 2 |
Numbers of the patients are shown.
Serial changes of TSBAb and TSAb over 10 years were studied in 34 TSBAb-positive patients with hypothyroidism (I) and in 98 TSAb-positive Graves' patients with hyperthyroidism (II). The 34 TSBAb-positive patients with hypothyroidism were treated with thyroxine (T4) and the 98 TSAb-positive Graves' patients with hyperthyroidism were treated with antithyroid drugs (ATDs). Half (17) (Ia) of the 34 TSBAb-positive patients with hypothyroidism (I) continued to have positive TSBAb and continued to have hypothyroidism. Ten (IIa) of the 98 TSAb-positive Graves' patients with hyperthyroidism (II) continued to have positive TSAb and continued to have Graves' hyperthyroidism. With the disappearance of TSBAb, recovery from hypothyroidism was noted in 13 (Ib1) (87%) of the 15 patients, in whom TSBAb had disappeared (Ib). With the disappearance of TSAb, remissions of Graves' hyperthyroidism were noted in 60 (IIc1) (82%) of the 73, in whom TSAb had disappeared (IIc). Two of the 34 TSBAb-positive patients with hypothyroidism developed TSAb-positive Graves' hyperthyroidism (Ic), and two of the 98 TSAb-positive Graves' patients with hyperthyroidism developed TSBAb-positive hypothyroidism (IId).